PULM Pulmatrix Inc.

1.58
-0.04  -2%
Previous Close 1.62
Open 1.54
Price To Book 2.13
Market Cap 31,591,405
Shares 19,994,560
Volume 284,270
Short Ratio
Av. Daily Volume 1,144,818
Stock charts supplied by TradingView

NewsSee all news

  1. Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement

    LEXINGTON, Mass., Jan. 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the

  2. Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies

    LEXINGTON, Mass., Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that

  3. Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

    LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that

  4. Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors

    LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the

  5. Pulmatrix Reports Q3 2019 Results

    LEXINGTON, Mass., Nov. 1, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) today reports its third quarter results. Q3 2019 Highlights Pulmatrix achieved clinical and business milestones

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 dosing has commenced with top-line data due 4Q 2020
Pulmazole (PUR1900)
Allergic bronchopulmonary aspergillosis in patients with asthma.
Phase 2a data due 4Q 2020.
PUR1800
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)
Phase 2 ready.
PUR0200
COPD

Latest News

  1. Pulmatrix Regains Compliance with Nasdaq Minimum Bid Price Requirement

    LEXINGTON, Mass., Jan. 16, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) announced today that it received a letter from the listing qualifications department staff of The Nasdaq Stock Market LLC, stating that the

  2. Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies

    LEXINGTON, Mass., Jan. 6, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that

  3. Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson

    LEXINGTON, Mass., Jan. 2, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases, today announced that

  4. Pulmatrix appoints Life Sciences Executive Rick Batycky to the Board of Directors

    LEXINGTON, Mass., Nov. 4, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced the

  5. Pulmatrix Reports Q3 2019 Results

    LEXINGTON, Mass., Nov. 1, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) today reports its third quarter results. Q3 2019 Highlights Pulmatrix achieved clinical and business milestones

  6. Pulmatrix and Cipla Announce First Patient Dosed in Phase 2 Trial Evaluating Pulmazole for Treatment of Allergic Bronchopulmonary Aspergillosis in Patients with Asthma

    LEXINGTON, Mass., Sept. 18, 2019 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ:PULM) today announced that the first patient has been dosed in the Phase 2 trial evaluating Pulmazole, an inhaled iSPERSE formulation of the